Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 4Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Observational 3Interventional 1

Sponsor

Cancer Type

Gynecologic 7Thoracic 5NET 4Endocrine 4Other solid neoplasm 2Other hematologic neoplasm 2Genitourinary 2Classical hematology 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Myeloid 1Lymphoid 1Head & Neck 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Neuroendocrine Tumors 4

Interventions

Everolimus 32Octreotide 15Cisplatin 14pasireotide 13Sunitinib 13Temozolomide 11pembrolizumab 10Etoposide 10Doxorubicin 10lanreotide 9Magnetic Resonance Spectroscopy 9Bevacizumab 9lutetium Lu 177 dotatate 8gallium Ga 68 dotatate 8Sorafenib 8Paclitaxel 83-Iodobenzylguanidine 8lenvatinib 7pazopanib 6Radiotherapy 6Positron Emission Tomography Computed Tomography 6surufatinib 5cabozantinib 5avelumab 5Thyrotropin Alfa 5Surgical Procedures, Operative 5Radiosurgery 5Nivolumab 5Mitotane 5Irinotecan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Data Collection × Endocrine × Clear all
NCT05017662 2025-09-04

A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072

Ariceum Therapeutics GmbH

Phase NA Completed
20 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03562091 2020-08-28

OPERA

Ipsen

Completed
115 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03112694 2020-06-02

Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors

Ipsen

Completed
93 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03220087 2018-12-21

RECOSY

Ipsen

Completed
142 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡